Már a háziorvos is felírhatja a koronavírus-betegeknek a favipiravir hatóanyagú gyógyszert - Portfolio.hu
Coronavirus | Drug launched for moderate COVID-19 cases - The Hindu
IMWP monographs on Favipiravir and on Favipiravir tablets published for public enquiry - European Directorate for the Quality of Medicines & HealthCare
Favilavir approved as experimental coronavirus drug
Glenmark launches Favipiravir for treatment of mild to moderate COVID-19 patients
Cipla to launch favipiravir under Ciplenza in August at 68 rupees per pill | Mint
Favipiravir shows good clinical efficacy in treating COVID-19: official - Xinhua | English.news.cn
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care - The Lancet Respiratory Medicine
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial — Nuffield Department of Primary Care Health Sciences, University of Oxford
Favipiravir 400Mg Tablet at Best Price in Delhi, Delhi | Corporate Opportunity Services
Drug firms race to launch Favipiravir as antiviral gains traction in mild-moderate COVID-19 care
Favipiravir as treatment for mild to moderate COVID-19 - Glenmark
Dr. Reddy's Avigan 200mg tablets available as unlicensed medicine :: C+D
Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet - India Today